Preview Mode Links will not work in preview mode

GRACEcast

Jan 26, 2013

Dr. Jack West reviews the encouraging results with selumetinib, a MEK inhibitor, in combination with chemotherapy for patients with advanced NSCLC and a KRAS mutation, the most common molecular marker seen in lung cancer. 


Jan 13, 2013

Dr. Ramalingam, from Winship Cancer Center at Emory University in Atlanta, dispels several myths that have created barriers to patient participation in clinical trials and highlights the rights of a patient interested in enrolling on a study.


Jan 13, 2013

Dr. Ramalingam, from Winship Cancer Center at Emory University in Atlanta, dispels several myths that have created barriers to patient participation in clinical trials and highlights the rights of a patient interested in enrolling on a study.


Jan 11, 2013

Dr. Ramalingam, from Winship Cancer Center at Emory University in Atlanta, explains the process of developing a clinical trial, from identifying the most important questions to navigating it through the design and implementation process and enrolling patients.


Jan 11, 2013

Dr. Ramalingam, from Winship Cancer Center at Emory University in Atlanta, explains the process of developing a clinical trial, from identifying the most important questions to navigating it through the design and implementation process and enrolling patients.